Regadenoson

Indies Pharma aims to generate revenue from its FDA-approved Regadenoson generic drug in the US market next year, following advanced distribution discussions. The drug, equivalent to Lexiscan, treats cardiovascular diseases, with US sales exceeding $600 million in 2023.

Indies Pharma Jamaica Limited aims to double revenues next year after FDA approval of its generic Regadenoson Injection, used for heart disease treatment. The company expects to hit $2 billion, possibly $3 billion by FY2025, with initial sales focused on the U.S. market.

Indies Pharma Jamaica is the first Jamaican company to have an ANDA approved by the FDA, unlocking a $400 million market for its generic drug Regadenoson, used for heart disease diagnostics. The company plans to divest its anti-cancer drug due to market shrinkage and aims to secure a distributor for its new drug in the U.S.

The article discusses challenges in treating CNS diseases due to the BBB's protective mechanisms, limiting drug delivery. It explores invasive and non-invasive strategies for drug delivery, including intrathecal administration, microneedles, and non-invasive methods like passive transcytosis, intranasal administration, and BBB disruption techniques using light and ultrasound. Ligands conjugation and membrane coating are also highlighted for targeted drug delivery to the brain.